Ligand-based adoptive T cell targeting CA125 in ovarian cancer
Open Access
- 5 September 2023
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 21 (1) , 1-12
Abstract
Background: Ovarian cancer (OC) is a highly aggressive gynecological malignancy prevalent worldwide. Most OC cases are typically diagnosed at advanced stages, which has led to a 5-year overall survival rate of less than 35% following conventional treatment. Furthermore, immune checkpoint inhibitor therapy has shown limited efficacy in the treatment of patients with OC, and CAR-T therapy has also demonstrated modest results owing to inadequate T cell infiltration. Therefore, novel strategies must be developed to enhance T cell persistence and trafficking within the OC tumor microenvironment. Methods: In this study, we developed a novel adoptive T-cell therapy for ovarian cancer based on a chimeric antigen receptor structure. We used a ligand-receptor binding motif to enhance the therapeutic effect of targeting CA125. Since mesothelin can naturally bind to CA125 with high affinity, we concatenated the core-binding fragment of mesothelin with the 4-1BB and CD3ζ signal fragments to assemble a novel CA125-targeting chimeric receptor (CR). The CAR structure targeting CA125 derived from the 4H11 antibody was also constructed. CR- and CAR-encoding RNA were electroporated into T cells to evaluate their antitumor activity both in vitro and in vivo. Results: While CR-T or CAR-T cells exhibited moderate activity against two ovarian cancer cell lines, T cells co-expressing CR and CAR exhibited a superior killing effect compared to T cells expressing either CR or CAR alone. Furthermore, upon interaction with ovarian tumors, the ability of CR and CAR T cells to release activation markers and functional cytokines increased significantly. Similarly, CR and CAR co-expressing T cells persistently controlled the growth of transplanted ovarian cancer tumors in NSG mice and significantly prolonged the overall survival of tumor-challenged mice. Transcriptome sequencing revealed that the survival and cytotoxicity of T cells co-expressing CR and CAR were significantly altered compared with those of T cells expressing either CR or CAR. Conclusion: Our findings demonstrate that CA125 targeting CR and CAR can synergistically kill ovarian cancer cells, indicating that CA125 targeting by the two binding motifs simultaneously in tumors may improve the therapeutic outcomes of ovarian cancer treatment.Keywords
All Related Versions
Funding Information
- Shanghai Science International Cooperation Project (2020MHZ026)
This publication has 42 references indexed in Scilit:
- Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3BMC Cancer, 2014
- Strength of PD-1 signaling differentially affects T-cell effector functionsProceedings of the National Academy of Sciences, 2013
- Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target ToxicityMolecular Therapy, 2013
- In VivoPersistence, Tumor Localization, and Antitumor Activity of CAR-Engineered T Cells Is Enhanced by Costimulatory Signaling through CD137 (4-1BB)Cancer Research, 2011
- Novel Monoclonal Antibodies Against the Proximal (Carboxy-Terminal) Portions of MUC16Applied Immunohistochemistry & Molecular Morphology, 2010
- A Binding Domain on Mesothelin for CA125/MUC16Journal of Biological Chemistry, 2009
- Relationship between CD107a expression and cytotoxic activityCellular Immunology, 2009
- Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discoveryCancer Letters, 2007
- Targeting tumours with genetically enhanced T lymphocytesNature Reviews Cancer, 2003
- lnterleukin-13 is a new human lymphokine regulating inflammatory and immune responsesNature, 1993